Tony Coles, remembered by many investors for engineering a $10 billion biotech deal in 2013, will become chief executive of Cerevel, the Pfizer neuroscience spinout to which Bain Capital has pledged up to $350 million in funding, the company announced Monday.
“From my perspective, the area of neuroscience drug discovery is the next frontier for life sciences,” Coles said in an interview. “It’s essentially what HIV AIDS and cancer were two decades ago.”
Since 2014, Coles has been the chairman and CEO of Yumanity, a startup focused on Alzheimer’s disease that he founded with MIT protein-folding expert Susan Linquist. In July, it was announced that Coles would be replaced as CEO there; he remains chairman. His last day there was Tuesday.